Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
复制标题
DOI：
10.1186/2008-2231-22-47
复制
发表时间：
2014-06-05
期刊：
影响因子：
--
通讯作者：
Heidari M
中科院分区：
文献类型：
--
作者：
Akbari A;Amanpour S;Muhammadnejad S;Ghahremani MH;Ghaffari SH;Dehpour AR;Mobini GR;Shidfar F;Abastabar M;Khoshzaban A;Faghihloo E;Karimi A;Heidari M
Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment. To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2′-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively. Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls. Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
登录
查看更多内容
影响因子：
11.5
作者：
Ge, Rongrong;Rajeev, Vaishali;Reiss, Michael
通讯作者：
Reiss, Michael
影响因子：
2.9
作者：
Peng, SB;Yan, L;Yingling, JM
通讯作者：
Yingling, JM
影响因子：
11.2
作者：
Uhl, M;Aulwurm, S;Weller, M
通讯作者：
Weller, M
影响因子：
11.2
作者：
Subramanian, G;Schwarz, RE;Reiss, M
通讯作者：
Reiss, M
影响因子：
64.5
作者：
Hill, R;Song, YR;Van Dyke, T
通讯作者：
Van Dyke, T